GLP-1 receptor agonists lead a new wave of therapeutic options that may benefit patients with osteoarthritis, according to ...

Anti-obesity drugs such as semaglutide (Ozempic, Wegovy) are also promising for the treatment of alcohol use disorder and alcohol-associated liver disease, as growing evidence suggests they reduce the ...

"Type 2 diabetes in children and teens is increasing at an alarming rate, yet treatment options are limited, and this patient population remains underserved," said Kenneth Custer, Ph.D., executive ...

As GLP-1 drugs reshape eating habits, the food industry faces new challenges - and opportunities - in sugar reduction, taste, ...

GLP-1 is a natural human hormone that regulates blood glucose levels. Scientists have now created long-lasting GLP-1 drugs ...

Obesity treatment is hurtling into a new era: once-a-week GLP-1 injections are edging toward the dramatic results of ...

India has cleared Ozempic, the once-a-week semaglutide injection from Novo Nordisk, for adults with type 2 diabetes.

In a further comparison using DPP-4i/SU as the reference, the GLP-1 RA/SGLT2i combination therapy had the greatest effect in ...

Ozempic may improve blood sugar a few weeks after starting, with full results appearing after about eight weeks. For weight ...

Efficacy of tirzepatide does not differ significantly between men and women, despite sex-specific differences in ...

Much excitement has built in recent years on the new class of incretin drugs that include glucagon-like-peptide-1 inhibitor (single agonists such as semaglutide) and also dual glucose-dependent ...

A popular class of therapies for treating diabetes and obesity may also have the potential to treat alcohol and drug addiction, according to a new paper published in the Journal of the Endocrine ...